From a clinical perspective, patients with NSCLC harboring these two mutations have demonstrated favorable therapeutic responses to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) [48,49], establishing them as an important first-line targeted treatment indication. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.